Investigating drug resistance in specific lung cancer mutations and developing targeted treatments
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors
This study is looking at how certain unusual changes in the EGFR gene make it harder for non-small cell lung cancer patients to respond to current treatments, and it's testing a new drug called poziotinib that might work better for those with these specific changes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10818397 on NIH RePORTER |
What this research studies
This research focuses on understanding the molecular features that contribute to drug resistance in non-small cell lung cancer (NSCLC) patients with atypical EGFR mutations, specifically those in exon 18 and exon 20. The study aims to develop novel inhibitors that selectively target these mutations, which are resistant to existing treatments. By analyzing the structural and functional characteristics of these mutations, researchers are working to identify effective therapies that can improve patient outcomes. The research includes clinical trials testing a promising drug, poziotinib, which has shown potential in treating these specific mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have atypical EGFR mutations in exon 18 or exon 20.
Not a fit: Patients with classical EGFR mutations or those without EGFR mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with atypical EGFR mutations in lung cancer, improving their survival and quality of life.
How similar studies have performed: Previous research has shown success with similar targeted therapies in other cancer types, indicating potential for this approach in treating atypical EGFR mutations.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Heymach, John V. — University of Tx Md Anderson Can Ctr
- Study coordinator: Heymach, John V.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.